Sun Pharma Advanced Q1 FY27 Results: Revenue Rs 39 Cr, Net Loss Rs 20 Cr and Key Highlights

Sun Pharma Advanced Q1 FY27 results were declared on August 10, 2026 on a consolidated basis. Revenue expanded +314.11% YoY to Rs 39 Cr from Rs 9.00 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.

Operating profit stood at Rs -36 Cr (+33.89% YoY). The company reported a net loss of Rs 20 Cr, providing the key financial picture for Sun Pharma Advanced Q1 FY27 results.

Click Here – Get Free Investment Predictions

Sun Pharma Advanced Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Sun Pharma Advanced Revenue	39	9.00	+314.11%
Operating Profit	-36	-54	+33.89%
Net Profit (PAT)	-20	-51	+59.94%
Reporting Basis	Consolidated

Sun Pharma Advanced Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Sun Pharma Advanced Q1 FY27 results reflect strong fundamentals. Revenue momentum were evident with the top line reaching Rs 39 Cr for the April to June 2026 quarter.

Operating profit expanded +33.89% YoY. Net loss of Rs 20 Cr indicates recovery is still in progress. Investors tracking Sun Pharma Advanced Q1 FY27 results will note these as key FY27 milestones.

Key Business Factors in Sun Pharma Advanced Q1 FY27 Results

Revenue Expansion in Q1 FY27

Sun Pharma Advanced Q1 FY27 results show revenue expanding +314.11% YoY to Rs 39 Cr from Rs 9.00 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.

Operating Margin Performance

Operating profit in Sun Pharma Advanced Q1 FY27 results stood at Rs -36 Cr (+33.89% YoY). Better cost absorption and product mix improvement contributed to the operating performance.

Net Loss and Recovery Roadmap

Net loss of Rs 20 Cr in Sun Pharma Advanced Q1 FY27 results highlights near-term headwinds. Management is implementing cost optimisation and revenue scaling to return to profitability.

Dividend Details

No dividend was declared alongside Sun Pharma Advanced Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.

FY27 Outlook for Sun Pharma Advanced

Sun Pharma Advanced is positioned to sustain growth momentum through FY27, backed by order visibility, operational improvements, and sector tailwinds in the pharmaceuticals space. Investors tracking Sun Pharma Advanced Q1 FY27 results should consult a SEBI-registered financial advisor before making decisions.

Sun Pharma Advanced Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced live price and get daily stock recommendations.

Sun Pharma Advanced shares were trading lower at Rs 207.38 (-2.73%) on August 10, 2026, reflecting investor sentiment on Sun Pharma Advanced Q1 FY27 results and the near-term sector outlook. The CMP of Rs 207.38 on the results date reflects broader sentiment toward the pharmaceuticals space.

Key Risks for Sun Pharma Advanced

Sector-Specific Risks

USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.

Valuation and Earnings Risk

Valuation risk remains if quarterly growth fails to sustain over the next two to three quarters.

Operational and Financial Risk

Subsidiary-level underperformance could drag consolidated PAT lower in subsequent quarters.

Conclusion

Sun Pharma Advanced Q1 FY27 results highlight near-term challenges with revenue at Rs 39 Cr and a net loss of Rs 20 Cr on a Consolidated basis. Execution of the recovery plan will be the key catalyst to watch in coming quarters.

Frequently Asked Questions on Sun Pharma Advanced Q1 FY27 Results

When were Sun Pharma Advanced Q1 FY27 results declared?

Ans. Sun Pharma Advanced Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Consolidated basis.

What was Sun Pharma Advanced revenue in Q1 FY27?

Ans. Revenue in Sun Pharma Advanced Q1 FY27 results was Rs 39 Cr, +314.11% YoY from Rs 9.00 Cr in Q1 FY26.

What was Sun Pharma Advanced PAT in Q1 FY27?

Ans. Net loss in Sun Pharma Advanced Q1 FY27 results was Rs 20 Cr (+59.94% YoY).

Did Sun Pharma Advanced declare a dividend in Q1 FY27?

Ans. No dividend was announced alongside Sun Pharma Advanced Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.

What is the FY27 outlook for Sun Pharma Advanced?

Ans. Management has guided revenue growth and margin improvement for FY27. Sector demand and execution will be key monitorables.

How did Sun Pharma Advanced stock react to Q1 FY27 results?

Ans. Sun Pharma Advanced shares were lower at Rs 207.38 (-2.73%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.